MATINAS BIOPHARMA HOLDINGS, INC. Net Fee Amt
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) had Net Fee Amt of $2.20 thousand as of 2026-06-16, per its S-3 filed 2026-06-16.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-06-16
- 2026-06-16: Net Fee Amt $2.20K.
| Period end | Net Fee Amt |
|---|---|
| 2026-06-16 | $2.20K S-3 · filed 2026-06-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |